---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-293373"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2023-12-12T23:59:59+00:00"
generated_at: "2026-06-07T14:08:05.394093+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Karyopharm receives Nasdaq deficiency notice for bid price below $1.00 per share

## Summary
- Received deficiency letter on Dec 6, 2023 for failing to meet Nasdaq's $1.00 minimum bid price rule for 30 consecutive business days.
- Has until June 3, 2024 to regain compliance by closing at $1.00+ for at least 10 consecutive business days.
- If non-compliant by June 3, may seek additional 180-day period by transferring to Nasdaq Capital Market and potentially effecting a reverse stock split.
- Company's common stock remains listed on Nasdaq Global Select Market during the 180-day compliance period.

## SEC filing metadata
- accession: 0001193125-23-293373
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2023-12-12T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312523293373/0001193125-23-293373-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312523293373/d647429d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-293373
- JSON: https://secwatch.observer/filing/0001193125-23-293373.json
- Plain text: https://secwatch.observer/filing/0001193125-23-293373.txt

## Key facts
- Listing & Compliance Notices
  Karyopharm Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)
  source text: December 6, 2023, Karyopharm Therapeutics Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). The deficiency letter does not result in the immediate delisting of the Company’s common stock from the Nasdaq Glo
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312523293373/0001193125-23-293373-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.